IRIS
ESPOSITO, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.557
EU - Europa 1.208
AS - Asia 1.008
SA - Sud America 100
AF - Africa 5
OC - Oceania 2
Totale 4.880
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.543
IE - Irlanda 698
SG - Singapore 403
CN - Cina 326
HK - Hong Kong 235
UA - Ucraina 152
DE - Germania 107
BR - Brasile 92
FR - Francia 57
SE - Svezia 48
IT - Italia 40
FI - Finlandia 32
GB - Regno Unito 22
TR - Turchia 18
BE - Belgio 15
CA - Canada 10
CZ - Repubblica Ceca 8
IN - India 8
NL - Olanda 7
LT - Lituania 6
VN - Vietnam 6
CO - Colombia 3
CR - Costa Rica 3
HU - Ungheria 3
TW - Taiwan 3
AR - Argentina 2
ES - Italia 2
IQ - Iraq 2
PT - Portogallo 2
RS - Serbia 2
RU - Federazione Russa 2
TN - Tunisia 2
AT - Austria 1
AU - Australia 1
BD - Bangladesh 1
BN - Brunei Darussalam 1
DK - Danimarca 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
GR - Grecia 1
HN - Honduras 1
IL - Israele 1
JP - Giappone 1
LU - Lussemburgo 1
MA - Marocco 1
NP - Nepal 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
UY - Uruguay 1
UZ - Uzbekistan 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 4.880
Salva come PNG Salva come JPEG
Città #
Dublin 696
Jacksonville 613
Chandler 469
Singapore 249
Santa Clara 247
Hong Kong 235
Boardman 155
Lawrence 102
Princeton 102
Nanjing 75
New York 72
Ann Arbor 71
Wilmington 66
Beijing 58
Dearborn 55
Shenyang 24
Los Angeles 23
Nanchang 22
Helsinki 20
Jinan 18
Hebei 17
Jiaxing 16
Ashburn 15
Brussels 15
Dallas 14
San Mateo 12
Izmir 11
Munich 11
Changsha 10
Des Moines 10
Council Bluffs 9
Brno 8
Norwalk 8
Houston 7
Kunming 7
Lappeenranta 7
Ningbo 7
Rome 7
Seattle 7
Tianjin 7
Woodbridge 7
Curitiba 6
Mountain View 6
São Paulo 6
Dong Ket 5
Guangzhou 5
London 5
Milan 5
Zhengzhou 5
Amsterdam 4
Falkenstein 4
Fremont 4
Hefei 4
Pune 4
Salvador 4
Budapest 3
Fairfield 3
Fortaleza 3
Mauá 3
Menlo Park 3
Redwood City 3
Ribeirão das Neves 3
Shanghai 3
Taizhou 3
Aci Catena 2
Aracaju 2
Bogotá 2
Bremen 2
Campinas 2
Chicago 2
Falls Church 2
Guaíba 2
Haikou 2
Hangzhou 2
Hyderabad 2
Istanbul 2
L'aquila 2
Lanzhou 2
Lorraine 2
L’Aquila 2
Madrid 2
Mumbai 2
Niš 2
Olbia 2
Ottawa 2
Paris 2
Pescara 2
Rio de Janeiro 2
San José 2
Taipei 2
Tappahannock 2
Toronto 2
Alajuela 1
Alegrete 1
Alenquer Municipality 1
Angra dos Reis 1
Aparecida de Goiânia 1
Arapongas 1
Araras 1
Ashington 1
Totale 3.742
Salva come PNG Salva come JPEG
Nome #
CONTINUOUS TREATMENT OF PLAQUE-TYPE PSORIASIS WITH ETANERCEPT: AN OBSERVATIONAL LONG-TERM EXPERIENCE 86
Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity 81
A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy 77
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. 74
Muir-Torre syndrome with fatal outcome 74
Dermatiti da Piogeni o Piodermiti 62
Treatment of erytrodermic psoriasis with etanercept 62
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 61
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 61
Systemic treatment: Ciclosporin 60
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 60
Influence and variation of the body mass index (BMI) in patients treated with etanercept for plaque-type psoriasis 55
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 55
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis 55
Treatment of early stage mycosis fungoides with topical bexarotene 54
Efficacy and safety of infliximab in teh treatment of severe or arthropathic psoriasis: preliminary results 53
Involvement of Ig heavy chain HS1,2-A enhancer*2 allele in dermatitis herpetiformis, plaque psoriasis and psoriatic arthritis 53
Association between psoriasis and periodontitis, and efficacy of anti-TNF-α therapy: a case series 53
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 52
Clinical Variants 51
Quality of life 51
Treatment of erythrodermic psoriasis with etanercept 51
Cutaneous body image in psoriasis: The role of attachment style and alexithymia 51
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis 50
Clinical applications of PPI-TT guidelines on transitioning therapies in the treatment of moderate to severe psoriasis: an expert opinion of central Italy dermatologists 49
Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept. 49
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience 49
Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice 48
Use of etanercept in patients with psoriasis and concomitant hepatitis C infection 47
An Italian study on psoriasis and depression 47
Histopathology of the skin in rheumatic diseases 47
Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis 47
Differences in percutaneous absorption in normal and atopic dermatitis skin in relation to molecular weigh. 46
High-dose initiation of etanercept in plaque psoriasis and psoriatic arthritis: an italian experience 46
UVA1 Laser in the Treatment of Vitiligo 46
Haplotypes associated with alleles of the immunoglobulin heavy chain enhancer HS1,2 of the 3¢ regulatory region in patients with psor- iatic arthritis 46
Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial 46
A case of generalized pustular psoriasis and arthritis treated with ixekizumab 46
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. 45
Topical corticotherapy: the expert's opinion 45
Long-lasting remission of pemphigus vulgaris treated with rituximab 45
Some considerations about the importance of alliance between patients and dermatologists in psoriasis 45
Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice 45
Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study 45
Dermatiti da piogeni o piodermiti 44
Association between Psoriasis and haplotypes of the IgH 3' Regulatory Region 1 44
UVB 308 nm XeCl excimer laser for mycosis fungoides 44
Unresponsiveness to etanercept: is there a common phenotipical profile of patients? 44
Psoriasis target therapy: ustekinumab 44
Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress 44
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study 44
Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience 44
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 43
Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. 43
Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis 43
PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study 43
Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis 42
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 42
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. 42
Morbid obesity and psoriasis: Disease remission after laparoscopic sleeve gastrectomy 42
Psoriasis and its management in women of childbearing age: Tools to increase awareness in dermatologists and patients 42
Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study 42
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 41
Survival rate of antitumour necrosis factor- treatments for psoriasis in routine dermatological practice: a multicentre observational study 41
High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients' quality of life 41
Etanercept, childhood and long-term safety: a case of five years treatment. 41
Long-term efficacy of etanercept in hidradenitis suppurativa. 41
INFLUENCE AND VARIATION OF THE BODY MASS INDEX IN PATIENTS TREATED WITH ETANERCEPT FOR PLAQUE-TYPE PSORIASIS 41
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis 41
Long-term efficacy of infliximab therapy in plaque psoriasis and arthropathic psoriasis 40
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series 40
Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity 40
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 40
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 40
Treatment of vitiligo with the 308 nm excimer laser 39
Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study 39
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 39
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic 39
Effect of anti tumor necrosis factor-alpha therapies on body composition in patients with psoriasis 38
Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management 38
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis 38
Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study 37
Trimethoprim-sulfamethoxazole induced erythrodermic psoriasis 37
Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis 37
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy 37
Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments An Observational Study 36
Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic 35
Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study 34
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 34
Increased frequency of Ig heavy-chain HS1,2-A enhancer *2 allele in dermatitis herpetiformis, plaque psoriasis, and psoriatic arthritis 33
Omalizumab for chronic spontaneous urticaria in “complex” patients: Data from real-life clinical practice 33
Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections 33
The therapeutic advantages on BMV plaster in chronic plaque psoriasis. Results from a new european multicentric study 32
From patients' needs to treatment outcomes in psoriasis: Results from the 'pSORRIDI' experience 32
Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis 32
Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study 32
Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care 32
Long-term treatment with etanercept monotherapy in a hemodialyzed patient with moderate-to-severe plaque-type psoriasis and psoriatic arthritis 31
Treatment of severe psoriasis during pregnancy and breastfeeding: A therapeutic challenging case 31
Risk of infections in psoriasis: assessment and challenges in daily management 31
Totale 4.543
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.712
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.712
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020215 0 0 0 0 0 0 0 0 101 27 6 81
2020/2021569 6 77 3 80 80 6 104 5 95 6 94 13
2021/2022334 7 4 19 11 24 4 3 25 66 4 37 130
2022/20231.613 121 66 15 139 98 133 5 99 840 10 58 29
2023/2024321 59 25 35 27 25 88 4 7 0 22 6 23
2024/20251.293 52 30 171 66 308 163 329 106 68 0 0 0
Totale 5.047